Brzezniak C, Oronsky B, Aggarwal R. Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.
Journal Publications
A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet
Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E. J Investig Med High Impact Case Rep. 2018 Mar 7.
Abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer
Oronsky B, Larson C, Reid T, Carter C. Journal of Investigative Medicine High Impact Case Reports, July 6, 2018.
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets
Ojemuyiwa M, Zeman K, Spira A, Oronsky B, Ray C, Trepel, JB, Lee MJ, Onyiuke I, Brzezniak C Clinical Case Reports, In Press. 2018
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials
Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S. Cancer Res. 2012 May 15;72(10):2600-8.
Real time dynamic imaging and current targeted therapies in the war on cancer: A new paradigm
Paulmurugan R, Oronsky B, Brouse C, Reid T, Knox S, Scicinski J. Theranostics. 2013 May 25;3(6):437-47.
The implications of hyponitroxia in cancer
Oronsky B, Fanger G, Oronsky N, Knox S, Scicinski J. Transl Oncol. 2014 Apr;7(2):167-73
Development of methods for the bioanalysis of RRx-001 and metabolites
Scicinski J, Oronsky B, Cooper V, Taylor M, Alexander M, Hadar R, Cosford R, Fleischmann T, Fitch W. Bioanalysis. 2014 Apr;6(7):947-56.
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
Ning S, Bednarski M, Oronsky B, Scicinski J, Knox S. Biochem Biophys Res Commun. 2014 May 9;447(3):537-42.
Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock
Brouse C, Ortiz D, Su Y, Oronsky B, Scicinski J, Cabrales P. Asian J Transfus Sci. 2015 Jan-Jun;9(1):55-60.
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
Yalcin O, Oronsky B, Carvalho L, Kuypers FA, Scicinski J, Cabrales P. Malar J. 2015 May 28;14:218.
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
Ning S, Sekar T, Scicinski J, Oronsky B, Peehl D, Knox S, Paulmurugan R. Oncotarget. 2015 Aug 28;6(25):21547-56.
Epigenetic approaches to overcoming chemotherapy resistance
Strauss J, Figg W. Lancet Oncol. 2015 Sep;16(9) 1013-1015
Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study
Reid T, Oronsky B, Scicinski J, Scribner C, Knox S, Ning S, Peehl D, Korn R, Stirn M, Carter C, Oronsky A, Taylor M, Fitch W, Cabrales P, Kim M, Burris H 3rd, Lao C, Abrouk N, Fanger G, Infante J. Lancet Oncol. 2015 Sep;16(9):1133-42.
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001
Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim M, Langecker P, Fanger G. Redox Biol. 2015 Dec;6:1-8
Epigenetic effects of RRx-001: A possible unifying mechanism of anticancer activity
Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl D. Oncotarget. 2015 Dec 22;6(41):43172-81.
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells
Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J. Oncotarget. 2016 Feb 23;7(8):9041-5.
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
Oronsky B, Scicinski J, Cabrales P, Minchinton A. Clin Epigenetics. 2016 May 11;8:53.
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
Sharma Das D, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson K. Leukemia 2016 May 24.
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B. Med Oncol. 2016 Jul;33(7):63.
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: A superagonist of nitric oxide generation.
Fens M, Cabrales P, Scicinski J, Larkin S, Suh J, Kuypers F, Oronsky N, Lybeck M, Oronsky A, Oronsky B. Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D. Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.
RRx-001 protects against cisplatin-induced toxicities.
Oronsky B, Reid T, Larson C, Carter C, Brzezniak C, Oronsky A, Cabrales P. J Cancer Res Clin Oncol. 2017 Apr 17. doi: 10.1007/s00432-017-2416-4.
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B. Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle G, Jagadish B, Mash E, Bruckheimer E, Oronsky B, Korn R. Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.
A note on improved statistical approaches to account for pseudoprogression
Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D. Cancer Chemother Pharmacol. 2018 March, 81(3): 621-626
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
Oronsky B, Reid T, Oronsky A , Caroen S, Carter C, Cabrales P. Oncotarget. 2018 Apr 5
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001
Oronsky B, Oronsky N, Cabrales P. J Cell Mol Med. 2018 Jul 16. doi: 10.1111/jcmm.13791
Pilot Study of the Antitumor Efficacy and Tolerability of Orally Administered Rrx-001 in Normal and Tumor-Bearing Mice
Ning S, Oronsky B, Scicinski J, Carter C, Knox S. J Cancer Res Therap Oncol 4: 1-6. September 18, 2018.
RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-α on monocytes/macrophages
Cabrales P. Translational Oncology Volume 12, Issue 4, April 2019, Pages 626-632
Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, et al. Society for NeuroOncology (SNO) 23rd Annual Meeting, Nov 15th-18th 2018, New Orleans, LA
RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
ASCO-SITC Clinical Immuno-Oncology Symposium, Feb 28th – Mar 2nd 2019
Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells
AACR Annual Meeting 2019. Atlanta, GA, March 29th – Apr 3rd, 2019.